PHealthy t1_j5weh0y wrote
Reply to comment by shiruken in The bivalent mRNA boosters from Pfizer-BioNTech and Moderna were 48% effective against symptomatic infection from the predominant omicron subvariant (XBB/XBB.1.5) in persons aged 18-49 years according to early data published by the CDC by shiruken
It's good to remember that vaccination coverage is just as important as efficacy.
shiruken OP t1_j5wfgxv wrote
Unfortunately only 15.3% coverage for the bivalent booster dose.
Viewing a single comment thread. View all comments